Li, Tian
Li, Tian was paid $852K by Medicaid between Jul 2021 and Nov 2024, across 145 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 16% of everything it billed.
GREENVILLE, NC 27834
Next to other Anatomic Pathology & Clinical Pathology Physician providers in North Carolina
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 10,777 | $141K | |
| 2022 | 28,676 | $280K | |
| 2023 | 32,000 | $243K | |
| 2024incomplete | 34,121 | $189K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 16% | 2,213 | 1,626 | $139K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 8.9% | 306 | 300 | $76K |
| 80053 | Comprehensive metabolic panel | 6.3% | 10,736 | 8,832 | $53K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.6% | 14,027 | 10,438 | $39K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.4% | 1,818 | 1,778 | $38K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.4% | 1,817 | 1,776 | $38K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.0% | 453 | 443 | $34K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.6% | 740 | 677 | $31K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.4% | 643 | 631 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.5% | 2,788 | 2,680 | $22K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.4% | 547 | 488 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 667 | 621 | $16K |
133 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 2,991 | $15K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 3,297 | $14K |
| 83735 | 1.5% | 3,643 | $12K | |
| 82803 | 1.4% | 952 | $12K | |
| 87480 | 1.3% | 906 | $11K | |
| 87510 | 1.3% | 906 | $11K | |
| 83605 | 1.0% | 1,547 | $9K | |
| 87660 | <1% | 1,046 | $8K | |
| 87040 | <1% | 874 | $8K | |
| 82962 | <1% | 3,848 | $8K | |
| 84484 | <1% | 1,407 | $8K | |
| 87081 | <1% | 2,627 | $7K | |
| 80061 | Lipid panel | <1% | 2,013 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 838 | $7K |
| 82330 | <1% | 865 | $7K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 503 | $7K |
| 87641 | <1% | 321 | $7K | |
| 83880 | <1% | 529 | $6K | |
| 88342 | <1% | 267 | $6K | |
| 85730 | <1% | 1,212 | $5K | |
| 87186 | <1% | 911 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 233 | $5K |
| 88341 | <1% | 85 | $5K | |
| 86780 | <1% | 576 | $4K | |
| 83690 | <1% | 1,281 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,373 | $4K |
| 86803 | <1% | 529 | $4K | |
| 85610 | <1% | 1,935 | $4K | |
| 82607 | <1% | 678 | $4K | |
| 81025 | <1% | 1,463 | $4K | |
| 84100 | <1% | 1,681 | $4K | |
| 86850 | <1% | 1,162 | $3K | |
| 80069 | <1% | 776 | $3K | |
| 82805 | <1% | 122 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 194 | $3K |
| 84439 | <1% | 712 | $3K | |
| 86140 | <1% | 1,268 | $3K | |
| 81001 | <1% | 2,026 | $3K | |
| 86901 | <1% | 1,267 | $3K | |
| 82728 | <1% | 705 | $3K | |
| 84466 | <1% | 654 | $3K | |
| 80202 | <1% | 371 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 93 | $2K |
| 83970 | <1% | 149 | $2K | |
| 82784 | <1% | 293 | $2K | |
| 86900 | <1% | 1,259 | $2K | |
| 82746 | <1% | 375 | $2K | |
| 85384 | <1% | 592 | $2K | |
| 87088 | <1% | 350 | $2K | |
| 83540 | <1% | 634 | $2K | |
| 88307 | <1% | 29 | $2K | |
| 82570 | <1% | 773 | $2K | |
| 87070 | <1% | 527 | $2K | |
| 82550 | <1% | 580 | $2K | |
| 85379 | <1% | 456 | $2K | |
| 81003 | <1% | 1,504 | $2K | |
| 87340 | <1% | 270 | $2K | |
| 85027 | <1% | 575 | $2K | |
| 87147 | <1% | 973 | $2K | |
| 84702 | <1% | 349 | $2K | |
| 80047 | <1% | 333 | $2K | |
| 87505 | <1% | 25 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 131 | $1K |
| 83615 | <1% | 395 | $1K | |
| 86038 | <1% | 159 | $1K | |
| 84703 | <1% | 314 | $1K | |
| 88189 | <1% | 29 | $1K | |
| 83516 | <1% | 180 | $1K | |
| 85014 | <1% | 743 | $983.68 | |
| 85652 | <1% | 774 | $971.64 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 118 | $919.15 |
| 82043 | <1% | 483 | $886.83 | |
| 80074 | <1% | 44 | $846.56 | |
| 87075 | <1% | 108 | $762.49 | |
| 87581 | <1% | 59 | $754.81 | |
| 87205 | <1% | 389 | $727.18 | |
| 80076 | <1% | 197 | $724.37 | |
| 84478 | <1% | 327 | $705.73 | |
| 84145 | <1% | 37 | $704.85 | |
| 86480 | <1% | 35 | $701.27 | |
| 82565 | <1% | 304 | $695.46 | |
| 87493 | <1% | 27 | $618.57 | |
| 84550 | <1% | 295 | $607.01 | |
| 87536 | <1% | 14 | $531.89 | |
| 82247 | <1% | 214 | $518.26 | |
| 86762 | <1% | 123 | $504.07 | |
| 88304 | <1% | 29 | $501.31 | |
| 85018 | <1% | 395 | $488.36 | |
| 82248 | <1% | 237 | $474.91 | |
| 86003 | <1% | 26 | $431.13 | |
| 88141 | <1% | 37 | $410.25 | |
| 85045 | <1% | 314 | $396.36 | |
| 84481 | <1% | 80 | $374.81 | |
| 84156 | <1% | 328 | $362.03 | |
| 86920 | <1% | 61 | $321.95 | |
| 82140 | <1% | 67 | $297.16 | |
| 84146 | <1% | 51 | $290.56 | |
| 87807 | <1% | 51 | $252.20 | |
| 86706 | <1% | 40 | $241.32 | |
| 82785 | <1% | 56 | $240.13 | |
| 80164 | <1% | 54 | $237.10 | |
| 80306 | <1% | 38 | $227.17 | |
| 80177 | <1% | 43 | $197.19 | |
| 83655 | <1% | 35 | $186.83 | |
| 87899 | <1% | 18 | $177.86 | |
| 87210 | <1% | 47 | $166.85 | |
| 84403 | <1% | 12 | $151.68 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 15 | $150.78 |
| 87427 | <1% | 20 | $125.00 | |
| 86431 | <1% | 38 | $123.16 | |
| 87045 | <1% | 20 | $123.00 | |
| 86880 | <1% | 41 | $120.85 | |
| 83001 | <1% | 13 | $118.17 | |
| 82533 | <1% | 13 | $117.43 | |
| 86360 | <1% | 13 | $112.77 | |
| 85049 | <1% | 71 | $99.08 | |
| 85347 | <1% | 37 | $96.94 | |
| 86359 | <1% | 13 | $90.56 | |
| 86695 | <1% | 12 | $87.98 | |
| 86308 | <1% | 37 | $85.20 | |
| 83930 | <1% | 25 | $64.08 | |
| 84480 | <1% | 14 | $63.84 | |
| 84300 | <1% | 30 | $58.30 | |
| 82950 | <1% | 29 | $58.29 | |
| 87046 | <1% | 20 | $56.60 | |
| 87184 | <1% | 12 | $54.00 | |
| 87102 | <1% | 12 | $46.50 | |
| 83050 | <1% | 17 | $41.82 | |
| 83935 | <1% | 14 | $32.63 | |
| 84132 | <1% | 12 | $31.50 | |
| 82009 | <1% | 12 | $19.04 | |
| 84157 | <1% | 15 | $18.00 | |
| 81015 | <1% | 13 | $17.03 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.